Research Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, 28029 Madrid, Spain.
Int J Mol Sci. 2021 Jun 16;22(12):6447. doi: 10.3390/ijms22126447.
Mitochondrial DNA depletion and multiple deletions syndromes (MDDS) constitute a group of mitochondrial diseases defined by dysfunctional mitochondrial DNA (mtDNA) replication and maintenance. As is the case for many other mitochondrial diseases, the options for the treatment of these disorders are rather limited today. Some aggressive treatments such as liver transplantation or allogeneic stem cell transplantation are among the few available options for patients with some forms of MDDS. However, in recent years, significant advances in our knowledge of the biochemical pathomechanisms accounting for dysfunctional mtDNA replication have been achieved, which has opened new prospects for the treatment of these often fatal diseases. Current strategies under investigation to treat MDDS range from small molecule substrate enhancement approaches to more complex treatments, such as lentiviral or adenoassociated vector-mediated gene therapy. Some of these experimental therapies have already reached the clinical phase with very promising results, however, they are hampered by the fact that these are all rare disorders and so the patient recruitment potential for clinical trials is very limited.
线粒体 DNA 耗竭和多种缺失综合征(MDDS)是一组由线粒体 DNA(mtDNA)复制和维持功能障碍定义的线粒体疾病。与许多其他线粒体疾病一样,这些疾病的治疗选择今天相当有限。一些积极的治疗方法,如肝移植或异体干细胞移植,是一些 MDDS 患者为数不多的可选治疗方法之一。然而,近年来,我们对导致 mtDNA 复制功能障碍的生化发病机制的认识取得了重大进展,为这些常致命疾病的治疗开辟了新的前景。目前正在研究的治疗 MDDS 的策略范围从小分子底物增强方法到更复杂的治疗方法,如慢病毒或腺相关载体介导的基因治疗。其中一些实验性疗法已经进入临床试验阶段,取得了非常有前景的结果,但由于这些都是罕见疾病,因此临床试验的患者招募潜力非常有限。